| Similar Articles |
|---|
 |
Chemistry World
December 5, 2014
Rebecca Trager |
Physicist turned politician to head AAAS Retiring US congressman Rush Holt, who happens to have a physics PhD, prepares to become the next chief executive officer of the American Association for the Advancement of Science. Funding for government science agencies is on his radar screen.   |
National Defense
November 2005
Margaret Davidson |
Biodefense Experts: Vaccines `At a Crossroads' Many of the companies seeking government funds for biodefense work are small firms with no experience in bringing a drug to market. And they face a significant challenge. |
Science News
March 14, 2009
Laura Sanders |
U.S. Science Remains Far From 'its Rightful Place' Rush Holt, a plasma physicist by training, represents New Jersey's 12th Congressional District in the U.S. Congress and discusses the state of science and science funding in the United States. |
Chemistry World
July 1, 2008
Rebecca Trager |
US research agencies get extra millions The US research community has won an extra $400 million for four science agencies, after successfully arguing that the nation's scientific enterprise is in a state of emergency. |
Bio-IT World
September 16, 2004
Zachary Zimmerman |
The Dark Side of Project BioShield Despite the uncertainties, an estimated 100 biopharma companies are developing anti-terror technologies. But they should examine both sides of Project BioShield before considering product development. |
Geotimes
February 2005
Katie Donnelly |
For Starters: Lame Duck Science and technology research and development did not escape the chopping block. The National Science Foundation received a 1.9 percent cut from last year -- the first cut to the agency in 13 years. |
HBS Working Knowledge
March 1, 2004
Martha Lagace |
Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends. |
Geotimes
March 2007
Linda Rowan |
A Change in Climate in Congress: To Act or Not To Act Because some state and local governments are taking action, Congress will need to set some federal standards in the near term. The nation can ill-afford a hodge-podge of regulations and policies on climate change across the country. |
Chemistry World
March 17, 2011
Hepeng Jia |
International recognition helps Chinese vaccine industry Vaccines made in China will now be supplied through United Nations agencies to developing countries, after recognition from the World Health Organisation that China's State Food and Drug Administration has complied with international standards for vaccine regulation. |
InternetNews
August 3, 2007
Roy Mark |
Competition Bill Passed to President's Desk The America Competes Act calls for doubling spending on research and math, science and engineering education. |
Geotimes
August 2004
Emily Lehr Wallace |
Budget Procrastination If the average American were aware enough of the budget process to be outraged by this governance via procrastination, perhaps the Congress would get the message and perform one of their central duties in an efficient and timely manner. |
Salon.com
March 8, 2001
Amy Standen |
Ready for some lockjaw? There's no profit in the tetanus vaccine business, so a rare and hideous disease may soon strike more Americans... |
National Defense
June 2007
Breanne Wagner |
Agencies Scramble to Create Vaccine Market Defense and Homeland Security are pursuing disparate vaccination programs to combat different needs for military and civilian populations. |
National Defense
June 2011
Eric Beidel |
Industry, Academia Race to Create Drugs Against Biological Warfare On the heels of anthrax comes a string of deadly agents that scientists also fear can be used as weapons and spread with ease. |
BusinessWeek
October 24, 2005
John Carey |
New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work? |
Reason
April 2008
Jeff Flake |
Passing Bad Laws A short guided tour -- by a congressman -- of the worst bills currently in Congress. |
InternetNews
April 26, 2007
Roy Mark |
Congress Gets Competitive With Bills Senate, House approve legislation aimed at improving America's global competitiveness. |
National Defense
September 2015
Craig R. McKinley |
Congress Should Follow Its Budget Rules Of the five members of the Joint Chiefs of Staff who will be leaving their positions or retiring this September, none ever had a defense budget passed on time under regular order following the procedures of the Budget Control Act of 1974 during their entire term in office. |
Pharmaceutical Executive
August 1, 2008
Patrick Clinton |
Cutter's Way It's time to get drug cases out of the courts entirely. |
BusinessWeek
July 25, 2005
Catherine Arnst |
O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
June 21, 2005
Brian Gorman |
Stem Cell Chatter Despite the promise suggested by early studies, embryonic stem cell research remains highly speculative. More concrete results, not the amount of cash being poured into research, are the best basis for investing decisions. |
The Motley Fool
December 1, 2008
Brian Orelli |
Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now. |
Salon.com
September 8, 2001
Jake Tapper |
The crusade against pork John McCain's moves to cut legislators' pet projects out of the federal budget aren't likely to gain many supporters, despite looming deficits... |
Scientific American
April 10, 2006
Christine Soares |
Turning Yellow Yellow fever shot confers long-lasting immunity, a trait that medical researchers hope to transfer to other kinds of vaccines. |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
The Motley Fool
April 29, 2010
Brian Orelli |
Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business. |
The Motley Fool
February 25, 2010
Brian Orelli |
13 Is Pfizer's Lucky Number Inherited from Wyeth, Prevnar 13 could be a goldmine for Pfizer. |
National Defense
August 2005
Joe Pappalardo |
Congress Poised to Act on Weak Bio-Preparedness Flaws in the U.S.' current defenses against dangerous diseases are numerous and institutional, according to experts. In response to these shortcomings, key congressional leaders are vowing action to fix the problems. |
Pharmaceutical Executive
May 1, 2006
Pasternak et al. |
Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity? |
Pharmaceutical Executive
January 1, 2006
Jill Wechsler |
Washington Report: PDUFA Blues The Prescription Drug User Fee Act is up for reauthorization. Let the games begin. |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
The Motley Fool
May 10, 2011
Brian Orelli |
Pfizer's Multibillion-Dollar Blockbuster Set to Grow Pfizer will make money off old people, too. |
Pharmaceutical Executive
June 1, 2005
Seth Berkley |
Backpage: Partnering for Vaccine Victories Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer. |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
